Extracorporeal Membrane Oxygenation for COVID-19: Case Report of Nine Patients

Jing Hua,Xin Zhang,Na Wang,Linyu Ran,Shengyun Wang,Chiungwei Huang,Wei Gao,Chenchen Qian,Wei Guo,Zhongmin Liu,Qiang Li,Feilong Wang
DOI: https://doi.org/10.3389/fmed.2021.697338
IF: 3.9
2021-11-12
Frontiers in Medicine
Abstract:Covid-19, Coronavirus disease 2019; ARDS, Acute respiratory distress syndrome; ECMO, Extracorporeal Membrane Oxygenation; WHO, World Health Organization; ICUs, Intensive care units. Acute respiratory distress syndrome (ARDS) is a fatal comorbidity of critically ill patients with COVID-19, who often end up on respiratory support. However, the safety and effectiveness of Extracorporeal Membrane Oxygenation (ECMO) in the treatment of COVID-19 remains to be elucidated at present. Here, we report on nine patients who received ECMO due to severe SARS-CoV-2 infection in Wuhan, China. Our initial experiences suggest that carefully selecting patients, as well as management by a well-trained team, are critical to implementing ECMO in patients with COVID-19. More randomized controlled trials with larger sample sizes are needed to evaluate the usefulness of ECMO in patients with COVID-19.
medicine, general & internal
What problem does this paper attempt to address?